thalidomide has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 6.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 5.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 2.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 1.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neymotin, A | 1 |
| Petri, S | 2 |
| Calingasan, NY | 2 |
| Wille, E | 1 |
| Schafer, P | 2 |
| Stewart, C | 2 |
| Hensley, K | 2 |
| Beal, MF | 2 |
| Kiaei, M | 2 |
| Kipiani, K | 1 |
| Gardian, G | 1 |
| Choi, DK | 1 |
| Chen, J | 1 |
| Muller, GW | 1 |
| Meyer, T | 1 |
| Maier, A | 1 |
| Borisow, N | 1 |
| Dullinger, JS | 1 |
| Splettstösser, G | 1 |
| Ohlraun, S | 1 |
| Münch, C | 1 |
| Linke, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)[NCT00231140] | Phase 2 | 40 participants | Interventional | 2005-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Thalidomide causes sinus bradycardia in ALS.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Arrhythmia, Sinus; Bradycardia | 2008 |
2 other studies available for thalidomide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight | 2009 |
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Cell Count; Cytokines; Di | 2006 |